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ABSTRACT
Introduction: The objective of this study was to
evaluate changes of patient characteristics and
surgical techniques in radical prostatectomy in
Germany within the last decade.
Methods: Data from 44 German prostate cancer
centers were included in the study. Patients’
characteristics (age, initial PSA value), surgical
techniques (open vs. minimally invasive
approaches), perioperative parameters
(operating time, rate of nerve-sparing (NS)
radical prostatectomies (RPs), hospitalization
time, catheter indwelling time, surgical margin
status, number of dissected lymph nodes (LN)),
and pathological findings (tumor stage, Gleason
score) were analyzed.
Results: Data from 11,675 patients who
underwent RP between 2005 and 2014 were
analyzed. The rate of open RP approaches
decreased by 1.7% (p = 0.0164), the rate of
minimally invasive approaches increased by
1.8% (p = 0.0164). Robot-assisted RPs (RARP)
increased by 4.6% (p\0.0001). The number of
NS procedures and pelvic lymphadenectomy
(LA) increased by 4.5% (p\0.0001) and 4.7%
(p\0.0001), respectively. Catheter indwelling
time and hospitalization time decreased by 1 day
(p\0.0001). No change in the rate of positive
surgical margins (p = 0.5061) and the ratio of
positive lymph nodes removed (p = 0.4628) was
observed. The number of Gleason B6 tumors
decreased significantly (p\0.0001).
Conclusions: The number of RARP has
significantly increased over the past decade and
there is a trend towards surgeries on more
advanced tumors with higher yields of lymph
nodes dissected. At the same time, the rate of
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nerve-sparing procedures has significantly
increased.
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INTRODUCTION
Prostate cancer is one of the most common
malignancies in men with more than 1 million
new cases being diagnosed worldwide every
year [1]. Despite a 5-year relative survival rate of
99.7% for all pathological stages, prostate
cancer remains the second leading cause of
cancer deaths in men [2, 3].
With the introduction of prostate-specific
antigen (PSA)-based prostate cancer screening
in the early 1990s, the annual number of
radical prostatectomies (RPs) performed in
Germany constantly increased until 2007
(source: Federal Statistical Office in Germany).
The relatively new concept of active
surveillance (AS) for low-risk prostate cancer
and the introduction of several alternative
treatment options in addition to modern
radiation therapy have led to a decrease of RP
numbers performed in Germany from 28,374
in 2006 to 21,850 in 2013 [4]. This translates
into a decline of approximately 930 RPs per
year throughout all prostate cancer centers in
Germany and does not necessarily reflect a
‘‘paradigm shift’’ towards active surveillance as
stated in the literature earlier [5].
Today, a patient’s individual decision between
surgery or alternative approaches is not just based
on relatively objective clinical parameters; instead,
individual factors such as family considerations,
social environment, social status, and factors like
comorbidities, patient–consultant relationship,
and logistic factors, such as accessibility to
hospitals and to the latest surgical techniques, are
gaining more and more importance [6].
While the number of RP procedures has
decreased over the last decade, the
technological progress made in the
performance of RP procedures has increased
especially since the introduction of the
robot-assisted radical prostatectomy (RARP) in
2000 [4, 7]. In the USA, RARP already represents
the most frequently used surgical approach for
treatment of localized prostate cancer. Current
data suggests that in 2008, 80% of RPs in the
USA were already robot-assisted and the
numbers are increasing [8, 9]. In comparison,
the proportion of robot-assisted prostatectomies
in Germany was 25.2% in 2013 [4].
Data from the literature and from the Federal
Statistical Office in Germany suggest a trend
towards an increase of minimally invasive RP
procedures performed in Germany over recent
years; however, no distinction was made
between conventional and robot-assisted
laparoscopy [10]. The purpose of this study
was to analyze the time trends with respect to
the utilization of RARP and conventional open
RP procedures performed in 44 German prostate
cancer centers over the last 9 years.
METHODS
A retrospective analysis of prostate cancer
patients who underwent RP between 2005 and
2014 was performed using an Internet-based
German database (http://www.prostata-ca.net)
that has been coordinated by the Berlin Cancer
Center (Berliner Tumorzentrum) since 2005. The
following parameters were evaluated in the
analysis: age, PSA value, RP technique, duration
of the surgery, nerve-sparing technique, hospi-
talization time, catheter indwelling time, surgi-
cal margin status, performance of lymph node
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dissection, lymph node involvement, pathologic
Gleason scores, and pathologic tumor stage. The
data was filtered (Excel 2013) according to
internal plausibility criteria and subdivided into
two groups: patients who underwent RP between
2005 and 2009 and patients who underwent RP
between 2010 and 2014.
We compared the clinical and pathological
characteristics of the study cohorts using
Chi-square test and Fisher exact test for
categorical variables and the Mann–Whitney
test for continuous variables. A p value less than
0.05 was considered statistically significant. All
statistical analyses were performed using
GraphPad Prism Version 5.00.
The datasets analyzed during the current
study are available from the corresponding
author on reasonable request.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Data from over 34,772 prostate cancer patients
who underwent RP in one of the participating
44 German centers between 1985 and 2014
were analyzed. Patients with missing data, such
as date of surgery and date of discharge from the
hospital, were excluded from the study. This
resulted in 11,675 datasets from 2005 to 2014
available for analysis.
The data from patients who underwent RP
between 2005 and 2014 was subdivided into two
eras: the era between 2005 and 2009, which
included data from 6600 patients, and the era
between 2010 and 2014, which included data from
5075 patients.
The mean age at the time of surgery of men
operated on between 2005 and 2009 was
65.0 years, while the mean age of patients
operated on in the second era was 65.7 years
(median 66.0 vs. 66.7, p\0.0001). There was no
statistically significant difference in the mean
initial PSA values between both eras.
The ratio of open RPs has decreased
significantly by 1.7% (81.9% vs. 80.2%,
p = 0.0164) in the analyzed time period mainly
because of a decrease in perineal RPs by 1.2%
(7.9% vs. 6.7%, p = 0.0153). Minimally invasive
procedures increased by 1.8% (18.0% vs. 19.8%,
p = 0.0164) because of an increase of RARPs by
4.6% (0.02% vs. 4.6%, p\0.0001). The classic
transperitoneal laparoscopic approach (LRPE)
decreased significantly (12.9% vs. 10.3%,
p\0.0001). No difference was found in the
percentage of endoscopic extraperitoneal
approaches (EERPE) (p = 0.6484) (Table 1, Fig. 1).
The median operation time of RP procedures
was 9 mins longer in the era between 2010 and
2014 than it was between 2005 and 2009 (144 vs.
153 min, p\0.0001). In 2010–2014 the rate of
nerve-sparing techniques was significantly more
utilized compared to 2005–2009 (58.7 vs. 63.2%;
p\0.0001). The median hospitalization time
decreased by 1 day (9 vs. 8 days, p\0.0001), as
did the catheter indwelling time (9.9 vs. 8.9 days,
p\0.0001). There was no difference observed
between the two eras concerning the surgical
margin status (p= 0.5061). The mean number of
dissected lymph nodes increased from 6.9 to 8.9
(p\0.0001), while the percentage of positive
nodes remained unchanged (4.0 vs. 3.1,
p= 0.4628). Furthermore, there was a significant
increase in the rate of pelvic lymphadenectomies
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performed between 2005 and 2014 (69.7% vs.
74.4%, p\0.0001) (Table 2).
Between 2010 and 2014 there were fewer
tumors operated on with pathologic Gleason
scores B6 than between 2005 and 2009 (4.1%
vs. 1.0% and 25.3% vs. 19.5%, p\0.0001). The
percentage of Gleason 7a (3 ? 4) tumors
remained constant and there was a significant
increase of Gleason 7b (4 ? 3) (16.3% vs. 19.7%,
p\0.0001), Gleason 9 (6.1% vs. 10.2%,
p\0.0001), and Gleason 10 (0.2% vs. 0.6%,
p = 0.0020) tumors (Table 3; Fig. 2).
While there was no change in the percentage
of pT2a and pT3a tumors being operated on
between 2010 and 2014 compared to between
2005 and 2009, there were significantly less
pT2b (2.8% vs. 1.6%, p\0.0001) and less pT2c
tumors (54.5% vs. 52.3%, p = 0.0321). In
contrast, the percentage of tumors with
seminal vesicle invasion (pT3b) increased
significantly (12.8% vs. 15.8%, p\0.0001).
The percentage of tumors that invade the
bladder and rectum (pT4) decreased between
2010 and 2014 compared to between 2005 and
2009 (1.9% vs. 0.9%, p\0.0001) (Table 4,
Fig. 3).
DISCUSSION
Over recent years there has been a significant
change in the management of localized prostate
cancer. As a result of recommendations against
PSA testing and screening there has been a
decline in RPs as well as pelvic lymph node
dissection (PLND) and high dose rate (HDR)
brachytherapy over recent years [11, 12].
Furthermore, more and more patients with
low-risk tumors are included in active
surveillance programs; patients with locally
advanced disease or lymph node metastases
are treated in multimodal concepts with surgery
and consecutive radiation therapy. At the same
time, the implementation of robot-assisted
surgery has led to a broader availability of
minimally invasive procedures for the
Table 1 Overview over the changes in surgical techniques over time
RP technique Era 2005–2009 Era 2010–2014 Difference p value
Percentage perineal RP (%) 7.9 6.7 -1.2 0.0153
Percentage retropubic RP (%) 74.0 73.5 -0.5 0.5037
Percentage of all open RP (%) 81.9 80.2 -1.7 0.0164
Percentage of robot-assisted RP (RARP) (%) 0.02 4.6 4.6 0.0001
Percentage of endoscopic extraperitoneal RP (EERPE) (%) 5.1 4.9 -0.2 0.6484
Percentage of laparoscopic transperitoneal RP (LRPE) (%) 12.9 10.3 -2.6 0.0001
Percentage of all minimally invasive RP (%) 18.0 19.8 1.8 0.0164
Fig. 1 Changes in the surgical management of prostate
cancer: comparison of data from 2005–2009 vs.
2010–2014
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treatment of prostate cancer. These trends were
also apparent in our database.
The current analysis has shown significant
changes in the surgical management of prostate
cancer: our data showed fewer surgeries of
patients with low-risk tumors, while more
patients with intermediate- and high-risk
cancer were operated on.
Our study showed an increase in the mean
age of men undergoing RP from 65.0 to
65.7 years. This seems to be consistent with
other findings in the literature that suggest an
overall trend to operate on older patients today
than was the case 10–15 years ago: single-center
data from a European tertiary-care institution
(Martini-Klinik) showed a mean patient age
increase of 3 years in men who underwent RP
over a time frame of 9 years between 2000 and
2009 [13]. Furthermore, an analysis from the
Federal Statistical Office in Germany that
evaluated all RPs performed in Germany in the
Table 2 Comparison of perioperative parameters over time
Perioperative parameter Era 2005–2009 Era 2010–2014 Difference p value
Median operating time (min) 144.0 153.0 9.0 0.0001
Rate of nerve-sparing operations (%) 58.7 63.2 4.5 0.0001
Median hospitalization time (days) 9.0 8.0 -1.0 0.0001
Median catheter indwelling time (days) 9.9 8.9 -1.0 0.0001
Positive surgical margin R1 (%) 25.8 25.6 -0.2 0.5061
Mean number of dissected lymph nodes 6.9 8.9 2.0 0.0001
% positive lymph nodes 4.0 3.1 -0.9 0.4628
Rate of pelvic LA (%) 69.7 74.4 4.7 0.0001
Table 3 Pathologic outcomes: proportion of patients with different pathologic Gleason scores
Pathologic Gleason score Era 2005–2009 Era 2010–2014 Difference p value
Gleason\6 (%) 4.1 1.0 -3.1 0.0001
Gleason 6 (%) 25.3 19.5 -5.8 0.0001
Gleason 7(3 ? 4) (%) 41.3 42.3 1.0 0.2875
Gleason 7(4 ? 3) (%) 16.3 19.7 3.4 0.0001
Gleason 8 (%) 6.3 6.6 0.3 0.523
Gleason 9 (%) 6.1 10.2 4.1 0.0001
Gleason 10 (%) 0.2 0.6 0.4 0.002
Fig. 2 Changes in the pathologic Gleason scores over time
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years 2013 and 2014 showed that in 2014, fewer
younger men (age 45–75) and more older men
(age 75–85 and age 90–95) underwent RP
compared to in 2013. Interestingly, this data
also showed that in 2014 fewer men were
operated on in the age group of 85–90 years
than was the case in 2013 (source: Federal
Statistical Office in Germany).
While no difference in the mean initial PSA
value over time was apparent in our analysis,
data from the Martini-Klinik showed a decrease
from 10.2 to 9.1 ng/ml in the mean PSA
between the years 2000 and 2009 [13]. As our
analysis, however, included data from 44
prostate cancer centers in Germany, this
finding might reflect clinical reality better
than data from a single center.
The current study shows that the
introduction of RARP implemented in more
and more centers led to a decrease of open RPs
during the study period of 9 years. Data from
the literature shows that while 1.5% of all
hospitals in Germany performed RPs using a
robot in 2006, this rate increased to 13% in
2013 [4]. The increase of RARP in our data was
4.6% over the study period and does not
necessarily reflect the reality in German
treatment; this discrepancy could be explained
by the fact that most of the participating
prostate cancer centers did not offer
robot-assisted surgery. However, the increase
of RARP procedures by 4.6% in 44 German
centers within 9 years seems to draw a realistic
picture when comparing our data with data
from the Federal Statistical Office which
evaluated the overall number of laparoscopic
procedures from all prostate cancer centers in
Germany: the rate of all laparoscopic RPs has
increased by 23.2% (13.4% in 2007 vs. 36.6% in
2014) within 7 years and open RP approaches
decreased by 23.1% (85.8% in 2007 vs. 62.7% in
2014, p\0.0001).
Therefore, by not exclusively analyzing data
from high volume centers like in the current
study the clinical reality in Germany might be
reflected quite realistically. However, one has to
keep in mind that the number of RARPs is
increasing rapidly, especially over the past
2 years, and that even recent data might be
outdated quickly. Overall, although the
frequency of RARP has increased significantly
Table 4 Pathologic outcomes: pathologic tumor stages
Pathologic T stage Era 2005–2009 Era 2010–2014 Difference p value
pT2a (%) 10.7 10.3 -0.4 0.6226
pT2b (%) 2.8 1.6 -1.2 0.0001
pT2c (%) 54.5 52.3 -2.2 0.0321
pT3a (%) 17.1 18.5 1.4 0.0545
pT3b (%) 12.8 15.8 3.0 0.0001
pT4 (%) 1.9 0.9 -1.0 0.0001
Fig. 3 Changes in the pathological T stage
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over the last few years, Germany is still at
another level compared to the USA, where
currently 70–85% of all RPs are performed
with a robot-assisted approach [8, 9].
The analysis of perioperative parameters in
this study showed an increase in the operation
time by 9 mins (144 vs. 153 min, p\0.0001), an
increase in nerve-sparing procedures by 4.5%
(p\0.0001), a shorter hospitalization time (9
vs. 8 days, p = 0.0001), and a shorter
catheter-indwelling time (9.9 vs. 8.9 days,
p = 0.0001), over the last 9 years. The increase
in the operating time could most likely be
explained by the increase in the usage of
robot-assisted surgery: according to data in the
literature, the operation time with RARP is
significantly longer compared to the operation
time with open surgery (184.4 vs. 128 min) [14].
Furthermore, the more frequent performance of
nerve-sparing procedures might have
contributed to a longer surgical time.
Our data showed an increase in
nerve-sparing procedures by 4.5% over study
period of 9 years (58.7% vs. 63.2%, p\0.0001).
This confirms the desire to achieve better
functional outcomes after surgery which can
be explained by the demographic changes in
highly developed countries and better
education of patients concerning the
preservation of continence and erectile
function. Unfortunately, we were not able to
extract postoperative functional data from the
database. Therefore we cannot conclude that
the higher rate of nerve sparing resulted in a
lower rate of erectile dysfunction following RP
[7, 15].
In patients included in our analysis the
median hospitalization time as well as the
catheter-indwelling time both significantly
decreased by 1 day during the study period of
9 years (9 vs. 8 days, 9.9 vs. 8.9 days,
p\0.0001). Beside the general aspects of
changing healthcare systems and the related
economic reasons in hospitals to keep hospital
stays for patients as short as possible, these
findings can also be explained by the fact that
according to data in the literature RARPs not
only promise better functional but also better
perioperative outcomes, e.g., a shorter
hospitalization and catheter indwelling time
with RARP compared to open RP [7, 14, 16]. A
similar analysis of data from the same database
showed that hospitalization time decreased by
2 days between 2005 and 2008 (10 vs. 8 days)
[10]. One argument of the advocates of RARP is
the reduced length of hospitalization and
therefore improved quality of life for the
patient [8]. However, there are also other
studies that show similar perioperative,
oncological, and functional outcomes for
laparoscopic RP compared to open and robotic
RP if surgeons were high volume surgeons [17].
In our analysis of patients operated on
between 2005 and 2014 we showed a
significant increase in the number of lymph
node dissections performed during RP (69.7%
vs. 74.4%, p\0.0001). We also demonstrated
that there has been a trend to operate on more
intermediate- and high-risk tumors (Gleason
7b, 8, 9, and 10) in the more recent era
compared to 9 years ago (Table 3). These
findings of an increase in lymph node
dissections and an increase in the surgery of
high-risk prostate cancers are closely connected
and can be explained by recently published
findings which showed that a multimodal
approach with RP combined with an extended
lymphadenectomy and/or adjuvant
radiotherapy can improve mortality up to
10–15%, especially in high-risk patients [18].
Additionally, the increase in lymph node
dissection is one of the main characteristics
that may be related to the use of RARP. It has
been described recently that pelvic lymph node
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dissection was more frequently performed at
RARPs (71.6%) compared to open RPs (66.2%)
[19].
The analysis of histopathological data
documented in our database showed a trend
towards the surgery of fewer low-risk tumors
(Gleason B6) and more intermediate- and
high-risk tumors over the last 9 years in
Germany: the rate of Gleason \6 tumors
operated on decreased by 3.1% (4.1% vs. 1.0%,
p\0.0001) and the rate of Gleason 6 tumors by
5.8% (25.3% vs. 19.5%, p\0.0001) while the
rate of Gleason 7b (16.3% vs. 19.7%,
p\0.0001), Gleason 9 (6.1 vs. 10.2%,
p\0.0001), and Gleason 10 (0.2% vs. 0.6%,
p = 0.0020) tumors operated on increased
significantly. The rate of Gleason 7a and
Gleason 8 tumors operated on remained
constant. Although when looking at the
overall numbers of RPs performed in Germany
active surveillance still seems
under-represented, the decrease of the ratio of
Gleason B6 tumors being operated on
according to our data suggests that there is at
least a trend towards higher active surveillance
rates in low-risk patients. This is also reflected in
the analysis of the pathologic tumor stage:
while we observed an increase in advanced
pT3b tumors (12.8% vs. 15.8%, p\0.0001) we
could demonstrate a decrease in pT2b and pT2c
tumors (2.8% vs. 1.6%, p\0.0001, 54.5% vs.
52.3%, p = 0.0321). This is in line with recently
published data from the USA that also
demonstrated a significant increase of T3a and
T3b tumors undergoing RP between 1998 and
2012 while alternative therapies like radiation
therapy decreased [20].
Further evaluation of the data from this
database is needed to analyze the ratio of
patients that have undergone active
surveillance. Current literature from other
countries showed that 15% of all patients
diagnosed with prostate cancer are already on
active surveillance [21]. Our analysis did not
include data about the number of positive
biopsies, the ratio of cancer within this biopsy,
or any information about the clinical T stage of
these patients, which is essential for clinical
decision-making. Additionally, before drawing
conclusions from the data analyzed in this
study one has to take into account the
weaknesses of data arising from a multicenter
Internet-based database like this. As there are
typically no study nurses or dedicated clinical
staff in the different centers responsible for
ensuring a timely and correct documentation of
complete data in all patients, the integrity of
the different parameters is not always given.
Thus, one major limitation of the current study
is the high percentage of patients with missing
data and/or lost to follow-up, which could have
resulted in a selection bias. Nevertheless, this
database is one of the biggest sources of data on
RP in Germany and therefore it most likely
represents the clinical reality in Germany.
CONCLUSION
Our data confirms the trend towards modern
laparoscopic surgical techniques. In particular,
robot-assisted radical prostatectomy is gaining
more and more importance across a broad range
of prostate cancer centers in Germany.
Furthermore, we demonstrated a decrease in
low-risk prostate cancer patients who
underwent RP. At the same time more
intermediate- and high-risk prostate cancer
patients are currently treated surgically.
Functional outcomes like the preservation of
erectile function and continence are gaining
more and more importance due to the raising
awareness and better education of patients as
well as the use of robotic systems.
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